World Journal of Stem Cells

Submit a Manuscript: https://www.f6publishing.com

World J Stem Cells 2025 June 26; 17(6): 103775

DOI: 10.4252/wjsc.v17.i6.103775

ISSN 1948-0210 (online)

REVIEW

Challenges in the clinical translation of stromal vascular fraction therapy in regenerative medicine

Naveen Jeyaraman, Sandeep Shrivastava, Ravi Velamoor Rangarajan, Arulkumar Nallakumarasamy, Swaminathan Ramasubramanian, Avinash Gandi Devadas, Secunda Rupert, Madhan Jeyaraman

Specialty type: Cell and tissue engineering

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's classification

Scientific Quality: Grade B, Grade B, Grade C, Grade C

Novelty: Grade B, Grade B, Grade C, Grade C

Creativity or Innovation: Grade B, Grade B, Grade B, Grade B

Scientific Significance: Grade B, Grade B, Grade B, Grade B

P-Reviewer: Apolonio EVP; Luo HC; Yang L

Received: December 3, 2024

Revised: March 13, 2025

Accepted: May 7, 2025

Published online: June 26, 2025

Processing time: 208 Days and 0.4 Hours

Naveen Jeyaraman, Sandeep Shrivastava, Arulkumar Nallakumarasamy, Department of Orthopaedics, Datta Meghe Institute of Higher Education and Research, Wardha 442004, Maharashtra, India

Naveen Jeyaraman, Ravi Velamoor Rangarajan, Arulkumar Nallakumarasamy, Swaminathan Ramasubramanian, Avinash Gandi Devadas, Madhan Jeyaraman, Department of Regenerative Medicine, Mother Cell Regenerative Centre, Tiruchirappalli 620017, Tamil Nadu, India

Secunda Rupert, Department of Regenerative Medicine and Research, Government Stanley Hospital, Chennai 600001, Tamil Nadu, India

Madhan Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India

Corresponding author: Madhan Jeyaraman, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com

Abstract

Stromal vascular fraction (SVF) therapy is a promising regenerative medicine strategy derived from adipose tissue, containing a heterogeneous mix of cells, including adipose-derived stem, endothelial, and immune cells. Despite its potential in treating conditions like osteoarthritis, chronic wounds, and myocardial ischemia, significant challenges impede its clinical translation. Key obstacles include biological variability in SVF composition, unclear mechanisms of action, regulatory ambiguities, and the technical difficulty of ensuring standardized and scalable isolation methods. Furthermore, patient-specific factors, ethical concerns, and the need for comprehensive efficacy assessment complicate clinical application. Addressing these challenges requires advancements in technology, regulatory flexibility, interdisciplinary collaboration, and personalized therapeutic approaches. Innovations such as automated isolation systems, advanced biomaterials, and CRISPR-based gene editing are potential solutions to improve the therapeutic reliability of SVF. A structured roadmap, including preclinical research, regulatory approval, and post-market surveillance, is proposed to advance SVF therapies from the laboratory to clinical practice. Future directions should focus on large-scale clinical trials, biomarker development, real-world evidence generation, and standardization of protocols to enhance the

safety, efficacy, and accessibility of SVF, ultimately realizing its potential as a versatile therapeutic in regenerative medicine.

Key Words: Stromal vascular fraction; Regenerative medicine; Cell therapy; Clinical translation; Adipose-derived stem cells

©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Stromal vascular fraction (SVF) therapy, derived from adipose tissue and containing a mix of cells, shows promise in treating conditions like osteoarthritis and chronic wounds. However, challenges such as biological variability, unclear mechanisms, regulatory issues, and scalability hinder clinical translation. Addressing these challenges requires technological advancements, regulatory flexibility, and interdisciplinary collaboration. Innovations like automated isolation, advanced biomaterials, and CRISPR-based editing could enhance reliability. A structured roadmap, including preclinical research and large-scale trials, is essential to advance SVF therapies. Future efforts should focus on standardizing protocols and generating real-world evidence to maximize the potential of SVF in regenerative medicine.

Citation: Jeyaraman N, Shrivastava S, Rangarajan RV, Nallakumarasamy A, Ramasubramanian S, Devadas AG, Rupert S, Jeyaraman M. Challenges in the clinical translation of stromal vascular fraction therapy in regenerative medicine. *World J Stem Cells* 2025; 17(6): 103775
URL: https://www.wjgnet.com/1948-0210/full/v17/i6/103775.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i6.103775

INTRODUCTION

Stromal vascular fraction (SVF) represents a heterogeneous mixture of cells derived from adipose tissue, encompassing a variety of cellular components such as mesenchymal stem cells (MSCs), endothelial cells, pericytes, and a multitude of immune cells (Table 1)[1]. SVF contains adipose-derived stem cells (ADSCs), which are a subset of MSCs known for their regenerative capabilities, alongside endothelial progenitor cells that contribute to angiogenesis, and various immune cells that play roles in immunomodulation and inflammation control[2-5]. This complex cellular milieu positions SVF as a promising candidate in regenerative medicine, offering multifaceted therapeutic potential across a spectrum of diseases and conditions. The therapeutic applications of SVF span numerous medical disciplines. In orthopedics, SVF has been employed to treat osteoarthritis, where its anti-inflammatory and regenerative properties help reduce joint pain and enhance mobility[1,6,7]. In cardiology, SVF therapy has shown promise in myocardial ischemia, facilitating myocardial tissue regeneration and improving cardiac function[8,9]. In the realm of plastic and reconstructive surgery, SVF is utilized to improve graft survival and enhance tissue regeneration, particularly in breast reconstruction procedures[10-13]. Furthermore, the immunomodulatory effects of SVF have been explored in wound healing, where it accelerates tissue repair and reduces inflammation, demonstrating its versatility in clinical applications.

Currently, SVF therapy is being explored in both clinical and preclinical settings, with a growing body of evidence supporting its efficacy and safety. Clinical studies, such as those conducted by Onoi *et al*[14] and Kim *et al*[15] have demonstrated the beneficial effects of SVF injections in reducing symptoms of hip osteoarthritis and enhancing cartilage repair, respectively. These studies highlight the potential of SVF in improving patient outcomes with minimal adverse effects.

Additionally, randomized controlled trials, like that by Zhang *et al*[16] have shown that SVF outperforms traditional treatments like hyaluronic acid in managing knee osteoarthritis, offering prolonged effectiveness and reduced risk of clinical failure. Despite these successes, the clinical translation of SVF therapy is not entirely devoid of limitations. Variability in SVF composition, lack of standardized protocols, regulatory hurdles, and technical challenges in SVF isolation and processing are significant impediments[1]. Moreover, the long-term efficacy and safety of SVF therapies remain under investigation, necessitating further research to fully establish their therapeutic potential[5,8,17]. The progression from understanding the cellular composition of SVF to its diverse clinical applications highlights the promising therapeutic potential of the heterogeneous cell population.

However, despite encouraging clinical outcomes across multiple specialties, significant challenges remain in standardizing and optimizing SVF therapy for widespread clinical adoption. This review aimed to provide a comprehensive analysis of the key challenges hindering the clinical translation of SVF therapy in regenerative medicine. All studies included in this review underwent verification for appropriate ethical approval documentation, patient consent procedures, and adherence to international research standards.

Table 1 Cellular composition and roles of stromal vascular fraction

Cell type	Proportion in SVF	Primary functions	Therapeutic implications
Adipose-derived stem cells	About 30%-40%	Multipotent differentiation, paracrine signaling, immunomodulation	Tissue regeneration, anti-inflammatory effects, angiogenesis
Endothelial cells	About 10%-15%	Formation of new blood vessels (angiogenesis), maintenance of vascular integrity	Enhancing blood supply to damaged tissues, improving graft survival
Pericytes	About 5%-10%	Stabilization of blood vessels, support of endothelial cells	Vascular stabilization, promoting tissue repair
Immune cells	About 20%-30%	Modulation of immune responses, inflammation control	Immunosuppression in autoimmune diseases, reducing chronic inflammation
Smooth muscle cells	About 5%	Regulation of blood vessel contraction and blood flow	Vascular remodeling, support of angiogenesis
Fibroblasts	About 5%	Extracellular matrix production, wound healing	Enhancing tissue structure and integrity during regeneration
Other cells	About 5%-10%	Various supportive and regulatory roles	Diverse contributions to tissue repair and immune modulation

SVF: Stromal vascular fraction.

BIOLOGICAL CHALLENGES

Heterogeneity of SVF composition

One of the foremost challenges in the clinical application of SVF therapy is the inherent heterogeneity in its cellular composition[4,18,19]. SVF derived from adipose tissue comprises a diverse array of cell types, including ADSCs, endothelial cells, pericytes, and various immune cells. This variability can be attributed to differences in donor characteristics, such as age, gender, body mass index, and metabolic health, as well as variations in isolation and processing techniques. For instance, studies like those conducted by Garza *et al*[20] and Jeon *et al*[21] have highlighted significant variability in SVF composition across different samples. Garza *et al*[20] reported dose-dependent improvements in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores in knee osteoarthritis patients, indicating that the therapeutic efficacy of SVF is influenced by the concentration and proportion of specific cell types within the fraction. Similarly, Jeon *et al*[21] demonstrated that SVF combined with fat grafting yielded higher fat retention rates, suggesting that the cellular composition of SVF plays a crucial role in tissue regeneration outcomes. This heterogeneity poses substantial challenges for the reproducibility of therapeutic outcomes. Variations in cell populations can lead to inconsistent efficacy, making it difficult to standardize treatments and predict patient responses[22-25]. Moreover, the lack of uniformity complicates the comparison of results across different studies, thereby hindering the establishment of robust clinical protocols.

Mechanism of action

Understanding the precise mechanisms through which SVF exerts its therapeutic effects is pivotal to optimize its clinical application. The therapeutic potential of SVF is largely attributed to the paracrine signaling of its constituent cells[8,26]. ADSCs secrete a plethora of cytokines, growth factors, and extracellular vesicles that modulate the microenvironment, promoting angiogenesis, reducing inflammation, and facilitating tissue repair[27-29]. In addition, SVF promotes fibroblast proliferation and contributes to extracellular matrix remodeling by promoting collagen synthesis and matrix metalloproteinase activity, which degrades damaged tissue and supports structural integrity[30]. Key factors such as vascular endothelial growth factor, transforming growth factor, and tumor necrosis factor play significant roles in these processes. Furthermore, SVF reduces chronic inflammation by secreting anti-inflammatory cytokines like interleukin-10 and shifting macrophages from the pro-inflammatory M1 phenotype to the reparative M2 phenotype[5]. This modulation limits fibrosis and promotes functional tissue regeneration. Angiogenesis is stimulated through the upregulation of endothelial-specific CD31 expression and the release of microRNA-containing exosomes that enhance vascular stability [31]. SVF also operates effectively in hypoxic and low-nutrient conditions, increasing epidermal growth factor and transforming growth factor-β1 secretion to sustain cell proliferation[30].

Despite this knowledge, the exact pathways and interactions governing the therapeutic actions of SVF remain partially elucidated. For example, Onoi *et al*[14] observed that SVF injections in the hip joint led to significant reductions in osteoarthritis symptoms, presumably through immunomodulatory and regenerative effects. However, the specific cellular interactions and molecular pathways involved in mediating these benefits are not fully understood. This gap in knowledge impedes the targeted enhancement of SVF therapies. Without a comprehensive understanding of how SVF components interact and contribute to tissue regeneration, it becomes challenging to manipulate these factors for improved therapeutic outcomes. Furthermore, the complexity of the cellular interactions of SVF necessitates advanced analytical techniques to dissect the underlying mechanisms, which are currently limited.




Figure 1 Biological and mechanistic challenges in stromal vascular fraction therapy. SVF: Stromal vascular fraction.

Longevity and efficacy

Another critical biological challenge is the limited lifespan and sustained efficacy of SVF cells post-transplantation. Once introduced into the target tissue, SVF cells must survive, integrate, and function effectively within the local environment to exert their therapeutic benefits[22,32-34]. In allogeneic scenarios, factors such as immune rejection, apoptosis, and unfavorable microenvironmental conditions can compromise cell survival and functionality. Zhang *et al*[16] demonstrated that SVF provided prolonged pain management and improved knee functionality for an average of 61.5 months, compared to the 30.3 months of hyaluronic acid. This suggests that SVF can offer sustained therapeutic benefits; however, the mechanisms underlying this prolonged efficacy are not entirely clear. Understanding the factors that influence cell longevity and efficacy is essential to enhance the therapeutic potential of SVF. Optimizing cell survival and integration involves several strategies, including preconditioning of SVF cells, use of biomaterials to support cell delivery, and genetic modification to enhance cell resilience[1]. Additionally, identifying biomarkers that predict cell viability and therapeutic outcomes can aid in patient stratification and personalized treatment approaches. Addressing these aspects is crucial to ensure the long-term success of SVF therapies in clinical settings. Biological challenges in SVF therapy are depicted in Figure 1.

REGULATORY CHALLENGES

Classification and standardization issues

The regulatory landscape for SVF therapies is complex and varies significantly across different jurisdictions. Regulatory agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) classify SVF products based on their intended use, processing methods, and cellular composition. Typically, SVF is categorized as a biological product or a medical device, depending on the extent of manipulation it undergoes before clinical application[35-38]. One of the primary challenges is the lack of standardized methods for SVF isolation, characterization, and storage. For instance, studies like those by Perdomo-Pantoja *et al*[39] and Choi *et al*[40] have utilized different enzymatic digestion and mechanical separation techniques to isolate SVF, leading to variability in cell yield and composition. This lack of standardization complicates the regulatory approval process, as consistent and reproducible manufacturing practices are essential to meet regulatory standards.

Moreover, the classification of SVF as either a minimally manipulated product or an advanced therapy medicinal product has significant implications for its regulatory pathway[41]. The FDA, for example, requires rigorous testing and approval processes for advanced therapy medicinal products, which can be time-consuming and costly. Conversely, if SVF is classified as minimally manipulated, it may be subject to less stringent regulations, potentially facilitating faster clinical translation but raising concerns about product consistency and safety.

Automated isolation systems have emerged as a promising approach to optimizing SVF processing by enhancing efficiency and standardization. Automated systems minimize variability, reduce contamination risks, and improve

Table 2 Comparison of regulatory frameworks for stromal vascular fraction therapy

Regulatory agency	Classification of SVF	Key requirements for approval	Pathway to market
FDA (United States)	Biological product or medical device	Comprehensive preclinical and clinical data. GMP. Detailed characterization of SVF	Investigational New Drug application. Biologics license application or device approval
EMA (EU)	Advanced therapy medicinal product	Robust clinical trial data. Compliance with GMP. Safety and efficacy demonstration	Marketing authorization application. Scientific advice and protocol assistance
Health Canada	Biological drug	Evidence of safety, efficacy, and quality. Adherence to GMP	Clinical trial application. New drug submission
TGA (Australia)	Biological therapeutic	Demonstrated safety and efficacy. Quality manufacturing processes	TGA submission
PMDA (Japan)	Regenerative medicine product	Extensive clinical data. Compliance with good clinical practice	Clinical trial notification. Marketing authorization

SVF: Stromal vascular fraction; FDA: Food and Drug Administration; EMA: European Medicines Agency; EU: European Union; TGA: Therapeutic Goods Administration; PMDA: Pharmaceuticals and Medical Devices Agency; GMP: Good manufacturing practices.

reproducibility compared to manual methods. Studies highlight that closed, enzyme-based systems ensure a higher yield of viable cells while maintaining sterility, thereby complying with good manufacturing practices (GMP)[42]. Additionally, integrating real-time monitoring technologies into these systems allows for precise control of enzymatic digestion, filtration, and centrifugation parameters, ensuring consistent SVF composition[1].

Advanced biomaterials for cell delivery further enhance the therapeutic potential of SVF by improving engraftment and cell viability. Hydrogels, for instance, provide a three-dimensional scaffold that supports cell adhesion and proliferation, optimizing the regenerative capacity of SVF in wound healing and cartilage repair applications[43]. Furthermore, incorporating bioactive molecules, such as growth factors or cytokines, within these scaffolds enhances SVF-mediated tissue regeneration by modulating the local microenvironment[30].

Flow cytometry-based characterization of SVF cell populations allows for the standardization of therapeutic cell doses and ensures the presence of key regenerative cell types while eliminating contaminants[5]. Additionally, cytokine profiling can be employed to assess the functional activity of SVF, providing insights into its immunomodulatory and anti-inflammatory properties[44]. Implementing these optimization strategies will enhance the clinical applicability of SVF in regenerative medicine.

Regulatory pathways and approval

Navigating the regulatory pathways for SVF therapies poses a substantial barrier to market entry and clinical application (Table 2). The FDA's guidelines for cell-based therapies necessitate comprehensive preclinical and clinical data demonstrating safety and efficacy. This includes detailed characterization of SVF products, quality control measures, and standardized manufacturing protocols[38]. The stringent requirements can delay the approval process and increase the financial burden on researchers and developers. Similarly, the EMA mandates that SVF therapies undergo rigorous evaluation before receiving marketing authorization within the European Union. This involves adherence to GMP, robust clinical trial data, and thorough safety assessments. The differences in regulatory frameworks between the FDA and EMA further complicate the global translation of SVF therapies, as developers must tailor their compliance strategies to meet diverse regulatory standards[45]. The regulatory landscape is further complicated by the rapid evolution of SVF therapies and the emergence of novel processing techniques. Regulatory agencies must continuously update their guidelines to accommodate advancements in cell therapy, necessitating ongoing dialogue between developers and regulators to ensure alignment and facilitate the approval process.

Safety and ethical concerns

Ensuring the safety of SVF therapies is paramount, given the potential risks associated with cell-based treatments. While studies such as those by Kwon *et al*[46] and Aletto *et al*[47] have reported minimal adverse effects following SVF administration, concerns remain regarding immune reactions, tumorigenicity, and the transmission of latent viruses when allogeneic usage is considered. The immunomodulatory properties of SVF cells, while beneficial to reduce inflammation, may also pose risks of unintended immune suppression or activation, necessitating careful monitoring and risk assessment.

Ethical considerations related to the sourcing of adipose tissue for SVF isolation also present significant challenges. The procurement of adipose tissue must adhere to ethical standards, ensuring informed consent and the protection of donor rights. Additionally, sourcing from vulnerable populations raises ethical concerns about exploitation and consent validity, necessitating stringent ethical guidelines and oversight mechanisms. The commercialization of SVF therapies also raises ethical questions regarding accessibility and equity. As SVF treatments are often expensive and not widely covered by insurance, there is a risk of creating disparities in access to these advanced therapies. Ensuring equitable access and preventing exploitation by unregulated clinics offering overpriced or unproven treatments is essential to maintain ethical standards in regenerative medicine[45]. Regulatory challenges in SVF therapy are depicted in Figure 2.




Figure 2 Regulatory challenges in stromal vascular fraction therapy. SVF: Stromal vascular fraction.

TECHNICAL AND LOGISTICAL CHALLENGES

SVF isolation and processing

The isolation and processing of SVF from adipose tissue involve several technical steps, each presenting its own set of challenges. Common methods include enzymatic digestion using collagenase and mechanical separation techniques such as centrifugation or filtration (Table 3)[44,48-51]. For example, Kim *et al*[15] utilized enzymatic digestion to isolate SVF cells, achieving a rapid and cost-effective preparation suitable for clinical applications. However, ensuring reproducibility and sterility across different clinical settings remains a significant hurdle. Variations in enzymatic digestion protocols, centrifugation speeds, and filtration techniques can lead to inconsistent cell yields and compositions, impacting therapeutic outcomes[52-54]. Additionally, maintaining sterility throughout the isolation process is critical to prevent contamination and ensure patient safety, necessitating stringent aseptic techniques and quality control measures. The variability in isolation methods complicates the standardization of SVF products, as different techniques may yield distinct cell populations with varying therapeutic potentials. This inconsistency hinders the ability to establish uniform treatment protocols and complicates the comparison of results across different studies and clinical trials.

Scalability and cost

Scaling up SVF processing for widespread clinical use presents both technical and financial challenges. The costs associated with SVF isolation, including enzymatic reagents, specialized equipment, and personnel training, can be substantial[55-57]. For instance, prospective studies by Mehling *et al*[58] and Aletto *et al*[47] have demonstrated the effectiveness of SVF therapies, yet the high costs of processing limit their accessibility and scalability. Emerging technologies aimed at reducing costs and simplifying procedures offer potential solutions. Innovations such as automated SVF isolation systems and cost-effective enzymatic reagents are being developed to streamline the processing workflow and minimize expenses. Additionally, advancements in microfluidics and bioreactor technologies hold promise to enhance the efficiency and scalability of SVF production, making it more feasible for large-scale clinical applications[59,60]. Despite these advancements, achieving cost-effective and scalable SVF processing requires ongoing research and investment. Addressing these challenges is crucial to make SVF therapies more accessible and economically viable, thereby facilitating their integration into mainstream clinical practice.

Quality control and storage

Ensuring the quality and viability of SVF cell products is essential to maintain therapeutic efficacy and patient safety. Quality control measures encompass various aspects, including cell viability assays, phenotypic characterization, and functional assessments. For example, the study by Perdomo-Pantoja *et al*[39] highlights the importance of robust quality control protocols in ensuring comparable fusion mass volume and radiographic fusion rates when SVF is combined with bone graft substitutes. Storage of SVF cells presents additional logistical challenges when culture of adipose-derived MSCs is contemplated[61,62]. Short-term storage typically involves cryopreservation techniques to maintain cell viability and functionality, while long-term storage requires optimized protocols to prevent cell degradation and ensure preservation of therapeutic potential[63-65]. Variability in storage conditions of SVF, such as temperature fluctuations and

Table 3 Comparison of stromal vascular fraction isolation methods

Isolation method	Technique description	Advantages	Challenges
Enzymatic digestion	Uses enzymes like collagenase to break down adipose tissue	High yield of viable cells. Effective separation of SVF	Potential for enzymatic damage. Regulatory concerns with enzyme use
Mechanical separation	Utilizes physical methods like centrifugation and filtration	Minimal enzymatic manipulation. Reduced regulatory barriers	Lower cell yield. Potential for contamination
Combination methods	Combines enzymatic and mechanical techniques	Balances cell yield and purity. Enhanced reproducibility	Increased complexity. Higher cost
Automated systems	Employs automated devices for consistent processing	Standardization across batches. Improved sterility	High initial investment. Limited accessibility
Non-enzymatic techniques	Uses methods like pressure-based separation	Avoids use of enzymes. Potentially lower cost	Variable cell yield. Less efficient separation

SVF: Stromal vascular fraction.

thawing protocols, can adversely affect cell quality, necessitating standardized storage procedures to maintain consistency[66-70]. Moreover, the integration of quality control and storage protocols within clinical workflows demands meticulous coordination and resource allocation. Implementing comprehensive quality assurance programs and investing in advanced storage facilities are imperative to ensure the reliability and consistency of SVF therapies. Technical and logistical challenges in SVF therapy are depicted in Figure 3.

CLINICAL AND TRANSLATIONAL CHALLENGES

Patient-specific factors

The efficacy and safety of SVF therapies are influenced by a myriad of patient-specific factors, including age, comorbidities, immune status, and overall health (Table 4). For instance, the study by Mehling *et al*[58] revealed that SVF cell therapy was more effective in patients with stage III arthritis compared to other stages, indicating that disease severity and patient condition significantly impact therapeutic outcomes. Age-related factors, such as the decline in stem cell function and regenerative capacity, can affect the efficacy of SVF therapies in older patients[71-74]. Comorbid conditions like diabetes and cardiovascular diseases may also alter the cellular environment, impacting SVF cell survival and integration.

Moreover, variations in immune status, whether due to immunosuppressive therapies or underlying autoimmune conditions, can influence the immunomodulatory effects of SVF cells, potentially leading to variable therapeutic responses[22]. These patient-specific factors necessitate tailored treatment approaches and personalized protocols to optimize SVF therapy outcomes. Additionally, these factors influence clinical study design, requiring stratification and careful patient selection to account for the diverse factors affecting efficacy and safety.

Customized SVF treatments account for patient-specific factors like age, health, comorbidities, and cellular regenerative potential. Elderly or chronically ill patients may have reduced cell viability, affecting therapy effectiveness. SVF volume is tailored to treatment goals, with larger volumes used for cartilage regeneration or joint function. Assessing prior treatment responses helps predict success, and *in vitro* manipulation of cells can enhance regenerative properties. Standardized protocols to harvest, process, and apply autologous SVF are essential for consistent, effective outcomes[1,5].

Outcome measures and efficacy assessment

Evaluating the efficacy of SVF therapies poses significant challenges due to the limitations of current outcome measures in clinical trials. Traditional metrics, such as pain reduction and functional improvement scores, provide valuable insights but may not fully capture the underlying biological changes induced by SVF treatments. For example, the WOMAC score used in Garza *et al*[20] provides a measure of pain and function in osteoarthritis patients, yet it does not directly assess the cellular or molecular mechanisms at play. To overcome these limitations, there is a need for the development of more comprehensive and objective biomarkers that can accurately reflect the therapeutic effects of SVF.

Biomarkers related to tissue regeneration, angiogenesis, and inflammation modulation can provide a more nuanced understanding of the impact of SVF[75-78]. Functional metrics, such as imaging-based assessments of tissue repair and biochemical markers of inflammation, can complement traditional outcome measures, offering a more holistic evaluation of therapeutic efficacy. Moreover, the integration of advanced analytical techniques, such as proteomics and genomics, can facilitate the identification of specific molecular signatures associated with successful SVF therapy outcomes. These improvements in efficacy assessment are crucial to establish robust evidence of the therapeutic benefits of SVF and to optimize treatment protocols based on objective data.

Interdisciplinary collaboration

The successful clinical translation of SVF therapies requires robust collaboration across multiple disciplines, including

Table 4 Patient-specific factors affecting stromal vascular fraction therapy

Factor	Impact on SVF therapy efficacy	Considerations for clinical trials
Age	Older patients may have reduced stem cell function and regenerative capacity	Stratify participants by age; analyze age-related efficacy differences
BMI	Obesity can affect adipose tissue quality and SVF cell composition	Control for BMI in study designs; assess cell quality based on BMI
Comorbidities	Conditions like diabetes and cardiovascular diseases may impair SVF integration	Exclude or specifically include certain comorbidities; subgroup analyses
Immune status	Immunosuppressed patients may have altered SVF cell behavior	Monitor immune markers; consider immunomodulatory effects
Gender	Potential differences in SVF cell composition and hormonal influences	Ensure balanced gender representation; analyze gender-specific outcomes
Medication use	Certain medications may influence SVF cell viability and function	Record and control for concurrent medication use; adjust protocols accordingly
Lifestyle factors	Smoking, alcohol use, and physical activity can affect tissue healing	Collect detailed lifestyle data; adjust for confounding variables
Genetic factors	Genetic variations may influence SVF cell behavior and therapeutic response	Consider genetic screening; explore personalized approaches

SVF: Stromal vascular fraction; BMI: Body mass index.




Figure 3 Technical and logistical challenges in stromal vascular fraction therapy. SVF: Stromal vascular fraction.

clinicians, researchers, regulatory experts, and industry stakeholders[79-82]. Interdisciplinary collaboration fosters the exchange of knowledge, facilitates the development of standardized protocols, and accelerates the translation of research findings into clinical practice. However, current gaps in communication and integration between different sectors hinder the clinical translation process. For instance, researchers may develop innovative SVF processing techniques without adequate consideration of regulatory requirements, leading to delays in approval and implementation. Similarly, clinicians may lack access to the latest research developments, limiting their ability to incorporate novel SVF therapies into patient care effectively. Enhancing interdisciplinary collaboration involves establishing platforms for regular communication, fostering joint research initiatives, and promoting the alignment of objectives between academic institutions and industry partners. Creating integrated networks that include regulatory agencies can also ensure that therapeutic developments follow regulatory standards, facilitating smoother clinical translation[83]. Moreover, fostering a culture of shared responsibility and mutual understanding among different stakeholders can bridge existing gaps, promoting a more cohesive approach to SVF therapy development and implementation. Addressing these collaborative challenges is essential to overcome the barriers to clinical translation and realize the full potential of SVF therapies in

regenerative medicine. Clinical and translational challenges in SVF therapy are depicted in Figure 4.




Figure 4 Clinical and translational challenges in stromal vascular fraction therapy.

ETHICAL AND SOCIAL CONSIDERATIONS

The deployment of SVF therapies in clinical practice raises several ethical concerns that must be carefully addressed to ensure responsible and equitable application. One primary ethical issue is patient consent, particularly concerning the sourcing of adipose tissue. Ensuring that patients provide informed consent, fully understanding the procedures, potential risks, and expected outcomes, is fundamental to ethical clinical practice[84-86].

Commercialization of adipose-derived cells also presents ethical dilemmas. The high costs associated with SVF therapies can limit access to affluent populations, exacerbating existing healthcare disparities. These challenges necessitate stringent donor screening, regulatory adherence, and ethical business practices to balance profit motives with patient welfare[1]. Additionally, *in vitro* expansion of autologous SVF for personalized therapies requires careful ethical oversight, ensuring transparent patient consent and responsible clinical application to uphold high ethical standards in regenerative medicine[1]. Furthermore, the proliferation of unregulated clinics offering SVF treatments without sufficient evidence of efficacy and safety raises concerns about exploitation and patient safety. Such practices can erode public trust in regenerative medicine and undermine the ethical foundations of clinical research and application.

Accessibility is another critical ethical consideration. Ensuring that SVF therapies are accessible to diverse populations, regardless of socioeconomic status, is essential to promote equity in healthcare[87,88]. Efforts must be made to prevent the commodification of SVF therapies and to ensure that treatments are distributed based on medical need rather than financial capability. Ethical sourcing of adipose tissue, particularly from vulnerable populations, requires stringent oversight to prevent exploitation and ensure donor rights are respected. Establishing ethical guidelines and regulatory frameworks that prioritize patient welfare and equitable access are crucial to address these ethical implications.

Managing patient expectations is vital for the ethical and effective application of SVF therapies. Patients may have high expectations regarding the potential benefits of SVF treatments, influenced by media reports, anecdotal evidence, and marketing by clinics offering unproven therapies[89]. These expectations can lead to disappointment and erosion of trust if the outcomes do not meet patient anticipations. Educating patients about the current state of SVF research, including its potential benefits and limitations, is essential to foster realistic expectations. Clear communication regarding the experimental nature of SVF therapies, the uncertainties surrounding long-term efficacy and safety, and the variability in treatment outcomes can help patients make informed decisions[90,91]. Accurate information dissemination through healthcare providers, patient education materials, and public health campaigns can mitigate the risk of exaggerated claims and prevent patients from pursuing unregulated or ineffective treatments. Additionally, developing standardized informational resources and guidelines for clinicians can enhance the quality and consistency of patient education, ensuring that individuals receive reliable and evidence-based information about SVF therapies[92,93]. Addressing patient expectations and promoting education not only enhance the ethical application of SVF therapies but also contribute to better patient outcomes and satisfaction by aligning treatment goals with achievable results.

Table 5 Innovative approaches to overcome stromal vascular fraction therapy challenges

Innovative approach	Description	Potential benefits	Current status
CRISPR-based gene editing	Modifying SVF cells to enhance regenerative capabilities and reduce immunogenicity	Improved cell survival and integration. Enhanced therapeutic efficacy	Preclinical research; limited clinical application
Advanced biomaterials	Development of scaffolds and hydrogels to support SVF cell delivery and function	Enhanced cell retention and viability. Controlled release of growth factors	Emerging technologies; ongoing research
Single-cell sequencing	Analyzing individual SVF cells to understand cellular heterogeneity and mechanisms	Identification of key therapeutic cell populations. Personalized treatment strategies	Active research; integration into SVF characterization
Automated isolation systems	Utilizing automated devices for consistent and sterile SVF processing	Standardized cell yields. Reduced contamination risk	Commercially available; increasing adoption
Bioreactor cultivation	Culturing progenitor cells in SVF in bioreactors to scale-up production and enhance cell properties	Large-scale production. Enhanced cell functionality	Pilot studies; early-stage commercialization
Potency assays development	Creating assays to evaluate SVF cell efficacy and functionality before clinical use	Improved quality control. Predictive markers for therapeutic outcomes	Ongoing development; essential for regulatory approval

SVF: Stromal vascular fraction.

FUTURE DIRECTIONS AND POTENTIAL SOLUTIONS

Advancements in technology and scientific research offer promising avenues to address the challenges associated with SVF therapy. Emerging technologies such as CRISPR-based gene editing[94,95] and the development of advanced biomaterials[96,97] can enhance the efficacy and safety of SVF treatments (Table 5). For example, gene editing techniques could be employed to modify SVF cells to improve regenerative capabilities or reduce immunogenicity, thereby enhancing their therapeutic potential.

Biomaterials, such as scaffolds and hydrogels, can provide supportive environments for SVF cells, promoting their survival, integration, and functionality within target tissues[98-100]. These materials can also be engineered to deliver growth factors and other bioactive molecules in a controlled manner, facilitating sustained therapeutic effects and enhancing tissue regeneration. Advancements in single-cell sequencing and proteomics can deepen our understanding of the cellular composition and mechanistic pathways of SVF, enabling the identification of specific cell populations and factors that drive therapeutic outcomes[101]. This knowledge can inform the development of more targeted and effective SVF therapies, optimizing their clinical application.

Regulatory science must evolve to accommodate the unique challenges posed by SVF therapies, striking a balance between fostering innovation and ensuring patient safety. Potential changes in regulatory policies could include the development of specific guidelines for SVF isolation and characterization, streamlined approval processes for minimally manipulated cell products, and the establishment of standardized protocols for SVF manufacturing and quality control [102,103]. Collaborative efforts between regulatory bodies, researchers, and industry stakeholders can facilitate the creation of harmonized regulatory frameworks that support the safe and efficient translation of SVF therapies into clinical practice. Additionally, adopting adaptive regulatory approaches that allow for iterative modifications based on emerging evidence can enhance the responsiveness of regulatory systems to scientific advancements. Implementing national registries and databases to track SVF therapy outcomes can also inform regulatory decisions, providing real-world evidence of safety and efficacy[104]. These registries can support post-market surveillance, enabling the identification and mitigation of potential risks and the continuous improvement of SVF therapy protocols[105].

A structured roadmap is essential to advance SVF therapies from research to widespread clinical application, progressing through key stages from preclinical research to post-market surveillance (Table 6). In the initial preclinical phase, comprehensive studies are necessary to clarify mechanisms of action, refine cell processing techniques, and assess both the safety and efficacy of SVF therapies within appropriate animal models. This foundational research should emphasize understanding the interactions between SVF cells and target tissues, with a focus on identifying biomarkers predictive of therapeutic outcomes. Once these initial studies have established a solid foundation, the next stage involves meticulous clinical trial design. Designing trials with robust methodologies, such as adequate sample sizes, randomized controlled structures, and standardized outcome measures, is essential to produce reliable evidence of the therapeutic potential of SVF.

Additionally, clinical trials should incorporate patient stratification based on specific variables like disease severity, age, and comorbidities to account for differences in treatment responses and enhance the relevance of results. Early engagement with regulatory authorities is a critical component of the development process, as it facilitates alignment with regulatory expectations, potentially expediting the approval timeline. Ensuring compliance with GMP and providing rigorous, comprehensive data on both safety and efficacy are essential to obtain regulatory approval. Following successful regulatory submission, the final phase centers on post-market surveillance, which establishes the mechanisms for continuous monitoring of SVF therapy outcomes in real-world clinical settings. This ongoing surveillance plays a pivotal role in identifying rare adverse events, evaluating the durability of therapeutic benefits, and supporting iterative improvements to SVF treatment protocols based on emerging clinical insights.

Table 6 Roadmap for clinical translation of stromal vascular fraction therapy

Stage	Key activities	Goals	Milestones
Preclinical research	Elucidate mechanisms of action. Optimize SVF isolation and processing techniques. Conduct animal studies	Understand SVF biology. Ensure safety and efficacy	Identification of key therapeutic pathways. Optimized protocols
Clinical trial design	Develop robust trial protocols. Define inclusion/exclusion criteria. Standardize outcome measures	Generate reliable efficacy and safety data	Successful completion of Phase I/II trials
Regulatory approval	Engage with regulatory bodies. Compile comprehensive data packages. Ensure GMP compliance	Achieve regulatory compliance. Facilitate market entry	Submission of IND/BLA or MAA Approval from FDA/EMA
Manufacturing scale-up	Implement GMP-compliant manufacturing. Establish quality control systems. Scale production capacity	Ensure consistent and high-quality SVF products	GMP certification. Scalable production lines
Market entry	Launch approved SVF therapies. Develop distribution channels. Train clinical practitioners	Introduce SVF therapies to the market. Ensure accessibility	Successful product launch. Initial clinical adoption
Post-market surveillance	Monitor long-term safety and efficacy. Collect real-world evidence. Implement continuous improvement	Ensure ongoing patient safety. Refine treatment protocols	Establishment of national registries. Regular safety reports

SVF: Stromal vascular fraction; GMP: Good manufacturing practices; IND: Investigational New Drug; BLA: Biologics license application; MAA: Marketing authorization application; FDA: Food and Drug Administration; EMA: European Medicines Agency.

Advancing the clinical translation of SVF therapies requires targeted research efforts across several critical domains (Tables 7 and 8). Mechanistic studies are essential to investigate the specific cellular and molecular mechanisms through which SVF exerts its therapeutic effects, as understanding the interactions between SVF cells and the host tissue microenvironment is fundamental to optimizing therapeutic strategies[106-108]. Additionally, conducting large-scale, multi-center clinical trials can generate robust evidence of the efficacy and safety of SVF across diverse patient populations. Such trials should focus on addressing current limitations, including small sample sizes and brief follow-up periods, to improve the generalizability and reliability of the findings.

Table 7 Suggested research directions for stromal vascular fraction therapy

Research area	Description	Objectives	Expected outcomes
Mechanistic studies	Investigate cellular and molecular pathways through which SVF exerts therapeutic effects	Understand SVF interactions with host tissues	Identification of key therapeutic targets
Large-scale clinical trials	Conduct multi-center, randomized controlled trials with larger and diverse patient populations	Validate efficacy and safety across different demographics	Robust evidence for regulatory approval and clinical guidelines
Biomarker development	Identify and validate biomarkers that predict therapeutic outcomes and monitor SVF efficacy in addition to the identified surface markers	Enhance personalized treatment approaches	Improved patient stratification and treatment optimization
Standardization of protocols	Develop and validate standardized methods for SVF isolation, processing, and administration	Ensure reproducibility and consistency in SVF therapies	Harmonized clinical protocols and regulatory compliance
Personalized medicine approaches	Tailor SVF therapies based on individual patient characteristics and disease profiles	Optimize therapeutic efficacy and minimize adverse effects	Personalized treatment plans enhancing patient outcomes
Real-world evidence generation	Collect and analyze data from SVF therapies in routine clinical settings to complement clinical trial data	Understand long-term effects and practical applications	Comprehensive understanding of SVF therapy performance in diverse settings
Integration with other therapies	Explore combination therapies involving SVF and other regenerative or pharmacological treatments	Enhance overall therapeutic efficacy	Synergistic treatment strategies improving patient outcomes

SVF: Stromal vascular fraction.

Generating real-world evidence is another key component, as analyzing outcomes from SVF therapies in practical, real-world settings can offer valuable insights into the long-term effects and applicability of SVF treatments. This type of evidence can inform clinical guidelines, influence regulatory decisions, and shape patient care practices. Furthermore, the standardization of protocols for SVF isolation, processing, and administration is crucial to achieve consistent therapeutic outcomes and ensure regulatory compliance. Collaborative efforts to establish consensus guidelines can promote uniformity and reproducibility across studies and clinical applications. Personalized medicine approaches are also worth exploring, as tailoring SVF treatments based on individual patient characteristics and disease profiles can enhance therapeutic efficacy and reduce adverse effects. By focusing on these specific research areas, the field can overcome existing challenges and unlock the full potential of SVF therapies in regenerative medicine.

Table 8 Ethical and social considerations in stromal vascular fraction therapy

Ethical/social aspect	Description	Implications	Strategies to address
Informed consent	Ensuring patients are fully aware of the procedures, risks, and benefits of SVF therapy	Ethical obligation to respect patient autonomy	Comprehensive consent forms. Clear communication of risks and benefits
Equitable access	Ensuring SVF therapies are accessible to all segments of the population regardless of socioeconomic status	Preventing healthcare disparities	Implementing insurance coverage. Subsidized treatment options
Commercialization and exploitation	Avoiding the commercialization of SVF therapies that exploit vulnerable patients	Protecting patients from unproven and overpriced treatments	Regulatory oversight. Strict marketing guidelines
Donor rights and ethical sourcing	Ensuring ethical procurement of adipose tissue, particularly from vulnerable populations	Respecting donor autonomy and preventing exploitation	Ethical sourcing protocols. Regulatory compliance
Public perception and trust	Maintaining public trust in regenerative medicine amidst unregulated clinic practices	Building and sustaining confidence in SVF therapies	Public education campaigns. Transparent clinical practices
Managing patient expectations	Aligning patient expectations with realistic therapeutic outcomes	Reducing disappointment and maintaining trust	Clear communication of therapy limitations and realistic outcomes
Regulatory compliance	Adhering to ethical and legal standards in SVF therapy development and application	Ensuring ethical integrity and patient safety	Ongoing regulatory training. Implementing best practice guidelines

SVF: Stromal vascular fraction.

CONCLUSION

SVF shows immense promise in regenerative medicine, offering a versatile therapeutic option across various medical fields. Its diverse cellular composition, including ADSCs and immune cells, supports tissue regeneration, immunomodulation, and anti-inflammatory effects, beneficial for conditions like osteoarthritis and chronic wounds. However, challenges span biological, regulatory, technical, clinical, ethical, and social areas. Biologically, the heterogeneity and mechanisms of SVF require further research for standardization. Regulatory ambiguities necessitate clearer guidelines, while technical hurdles demand scalable, sterile, and cost-effective isolation processes. Clinically, patient-specific factors and outcome measures need tailored approaches, and ethical issues such as equitable access and informed consent are critical. Advancements in technology, regulatory science, and interdisciplinary collaboration are vital to fully realize the clinical potential of SVF.

FOOTNOTES

Author contributions: Jeyaraman N designed the study; Jeyaraman N and Nallakumarasamy A analyzed the articles for review; Jeyaraman N, Nallakumarasamy A, and Ramasubramanian S wrote the manuscript; Shrivastava S, Rangarajan RV, Devadas AG, Rupert S, and Jeyaraman M finalized the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country of origin: India

ORCID number: Naveen Jeyaraman 0000-0002-4362-3326; Ravi Velamoor Rangarajan 0009-0006-7303-8474; Arulkumar Nallakumarasamy 0000-0002-2445-2883; Swaminathan Ramasubramanian 0000-0001-8845-8427; Madhan Jeyaraman 0000-0002-9045-9493.

S-Editor: Wang JJ
L-Editor: Filipodia
P-Editor: Zhang XD

REFERENCES

1 **Jeyaraman N**, Shrivastava S, Ravi VR, Nallakumarasamy A, Pundkar A, Jeyaraman M. Understanding and controlling the variables for

stromal vascular fraction therapy. *World J Stem Cells* 2024; **16**: 784-798 [*RCA*] [PMID: 39219728 DOI: 10.4252/wjsc.v16.i8.784] [FullText] [Full Text(PDF)]

2 **Biniazan F**, Stoian A, Haykal S. Adipose-Derived Stem Cells: Angiogenetic Potential and Utility in Tissue Engineering. *Int J Mol Sci* 2024; **25**: 2356 [*RCA*] [PMID: 38397032 DOI: 10.3390/ijms25042356] [FullText] [Full Text(PDF)]

3 **Kilinc MO**, Santidrian A, Minev I, Toth R, Draganov D, Nguyen D, Lander E, Berman M, Minev B, Szalay AA. The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of stem-cell therapy. *Clin Transl Med* 2018; **7**: 5 [*RCA*] [PMID: 29417261 DOI: 10.1186/s40169-018-0183-8] [FullText] [Full Text(PDF)]

4 **Sharma S**, Muthu S, Jeyaraman M, Ranjan R, Jha SK. Translational products of adipose tissue-derived mesenchymal stem cells: Bench to bedside applications. *World J Stem Cells* 2021; **13**: 1360-1381 [*RCA*] [PMID: 34786149 DOI: 10.4252/wjsc.v13.i10.1360] [FullText] [Full Text(PDF)]

5 **Goncharov EN**, Koval OA, Igorevich EI, Encarnacion Ramirez MJ, Nurmukhametov R, Valentinovich KK, Montemurro N. Analyzing the Clinical Potential of Stromal Vascular Fraction: A Comprehensive Literature Review. *Medicina (Kaunas)* 2024; **60**: 221 [*RCA*] [PMID: 38399509 DOI: 10.3390/medicina60020221] [FullText]

6 **Jeyaraman M**, Jeyaraman N, Jayakumar T, Ramasubramanian S, Ranjan R, Jha SK, Gupta A. Efficacy of stromal vascular fraction for knee osteoarthritis: A prospective, single-centre, non-randomized study with 2 years follow-up. *World J Orthop* 2024; **15**: 457-468 [*RCA*] [PMID: 38835682 DOI: 10.5312/wjo.v15.i5.457] [FullText] [Full Text(PDF)]

7 **Tantuway V**, Jeyaraman M, Nallakumarasamy A, Prikh MB, Sharma AK, Sharma R. Functional Outcome Analysis of Autologous Stromal Vascular Fraction (SVF) (Sahaj Therapy(®)) Using Direct Sonication in Osteonecrosis of the Femoral Head (ONFH): A 6-Year Follow-Up Study. *Indian J Orthop* 2024; **58**: 68-78 [*RCA*] [PMID: 38161400 DOI: 10.1007/s43465-023-01041-y] [FullText]

8 **Gareev I**, Beylerli O, Ilyasova T, Ahmad A, Shi H, Chekhonin V. Therapeutic application of adipose-derived stromal vascular fraction in myocardial infarction. *iScience* 2024; **27**: 109791 [*RCA*] [PMID: 38736548 DOI: 10.1016/j.isci.2024.109791] [FullText] [Full Text(PDF)]

9 **Yan W**, Xia Y, Zhao H, Xu X, Ma X, Tao L. Stem cell-based therapy in cardiac repair after myocardial infarction: Promise, challenges, and future directions. *J Mol Cell Cardiol* 2024; **188**: 1-14 [*RCA*] [PMID: 38246086 DOI: 10.1016/j.yjmcc.2023.12.009] [FullText]

10 **Mantovani GP**, Marra C, De Maria F, Pinto V, De Santis G. Adipose-derived stromal vascular fraction (SVF) for the treatment of androgenic alopecia (AGA): a systematic review. *Acta Biomed* 2023; **94**: e2023236 [*RCA*] [PMID: 37850761 DOI: 10.23750/abm.v94i5.15069] [FullText]

11 **Zocchi ML**, Prantl L, Oliinyk D, Knoedler L, Siegmund A, Ahmad N, Duscher D, Larcher L, Raposio E, Pagani A. Potential benefits of adipose–derived SVF and MSCs to regenerate damaged tissues from alloplastic synthetic materials. *Eur J Plast Surg* 2024; **47**: 48 [*RCA*] [DOI: 10.1007/s00238-024-02196-z] [FullText]

12 **Malekzadeh H**, Tirmizi Z, Arellano JA, Egro FM, Ejaz A. Application of Adipose-Tissue Derived Products for Burn Wound Healing. *Pharmaceuticals (Basel)* 2023; **16**: 1302 [*RCA*] [PMID: 37765109 DOI: 10.3390/ph16091302] [FullText]

13 **Cai W**, Yu LD, Tang X, Shen G. The Stromal Vascular Fraction Improves Maintenance of the Fat Graft Volume: A Systematic Review. *Ann Plast Surg* 2018; **81**: 367-371 [*RCA*] [PMID: 30095540 DOI: 10.1097/SAP.0000000000001589] [FullText]

14 **Onoi Y**, Matsumoto T, Sobajima S, Tsubosaka M, Hayashi S, Matsushita T, Iwaguro H, Kuroda R. Clinical use of autologous adipose-derived stromal vascular fraction cell injections for hip osteoarthritis. *Regen Ther* 2023; **24**: 94-102 [*RCA*] [PMID: 37363753 DOI: 10.1016/j.reth.2023.06.006] [FullText]

15 **Kim YS**, Oh SM, Suh DS, Tak DH, Kwon YB, Koh YG. Arthroscopic Implantation of Adipose-Derived Stromal Vascular Fraction Improves Cartilage Regeneration and Pain Relief in Patients With Knee Osteoarthritis. *Arthrosc Sports Med Rehabil* 2023; **5**: e707-e716 [*RCA*] [PMID: 37388866 DOI: 10.1016/j.asmr.2023.03.013] [FullText] [Full Text(PDF)]

16 **Zhang S**, Chen J, Zhang H, Hu S, Tong P, Shen J. Multiple intra-articular injections of autologous stromal vascular fractions for the treatment of multicompartmental osteoarthritis in both the tibiofemoral and patellofemoral joint: a single-blind randomized controlled study. *Postgrad Med J* 2024; **100**: 399-406 [*RCA*] [PMID: 38311348 DOI: 10.1093/postmj/qgae009] [FullText]

17 **Wu V**, Klein-Nulend J, Bravenboer N, Ten Bruggenkate CM, Helder MN, Schulten EAJM. Long-Term Safety of Bone Regeneration Using Autologous Stromal Vascular Fraction and Calcium Phosphate Ceramics: A 10-Year Prospective Cohort Study. *Stem Cells Transl Med* 2023; **12**: 617-630 [*RCA*] [PMID: 37527504 DOI: 10.1093/stcltm/szad045] [FullText]

18 **Zinger G**, Gronovich Y, Lotan AM, Sharon-Gabbay R. Pilot Study for Isolation of Stromal Vascular Fraction with Collagenase Using an Automated Processing System. *Int J Mol Sci* 2024; **25**: 7148 [*RCA*] [PMID: 39000252 DOI: 10.3390/ijms25137148] [FullText]

19 **Ramakrishnan VM**, Boyd NL. The Adipose Stromal Vascular Fraction as a Complex Cellular Source for Tissue Engineering Applications. *Tissue Eng Part B Rev* 2018; **24**: 289-299 [*RCA*] [PMID: 28316259 DOI: 10.1089/ten.TEB.2017.0061] [FullText]

20 **Garza JR**, Campbell RE, Tjoumakaris FP, Freedman KB, Miller LS, Santa Maria D, Tucker BS. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. *Am J Sports Med* 2020; **48**: 588-598 [*RCA*] [PMID: 32109160 DOI: 10.1177/0363546519899923] [FullText]

21 **Jeon HJ**, Choi DH, Lee JH, Lee JS, Lee J, Park HY, Yang JD. A Prospective Study of the Efficacy of Cell-Assisted Lipotransfer with Stromal Vascular Fraction to Correct Contour Deformities of the Autologous Reconstructed Breast. *Aesthetic Plast Surg* 2021; **45**: 853-863 [*RCA*] [PMID: 32995982 DOI: 10.1007/s00266-020-01981-y] [FullText]

22 **Dykstra JA**, Facile T, Patrick RJ, Francis KR, Milanovich S, Weimer JM, Kota DJ. Concise Review: Fat and Furious: Harnessing the Full Potential of Adipose-Derived Stromal Vascular Fraction. *Stem Cells Transl Med* 2017; **6**: 1096-1108 [*RCA*] [PMID: 28186685 DOI: 10.1002/sctm.16-0337] [FullText] [Full Text(PDF)]

23 **Kostecka A**, Kalamon N, Skoniecka A, Koczkowska M, Skowron PM, Piotrowski A, Pikuła M. Adipose-derived mesenchymal stromal cells in clinical trials: Insights from single-cell studies. *Life Sci* 2024; **351**: 122761 [*RCA*] [PMID: 38866216 DOI: 10.1016/j.lfs.2024.122761] [Full Text]

24 **Roshdy OH**, Abdallah WI, Farid CI, Mehanna RA, Bayoumi NH, Ismail AI. Stromal vascular fraction improves the durability of autologous fat temple augmentation-A split-face randomized study using ultrasound biomicroscopy. *J Plast Reconstr Aesthet Surg* 2022; **75**: 1870-1877 [*RCA*] [PMID: 35125305 DOI: 10.1016/j.bjps.2021.12.005] [FullText]

25 **Cremona M**, Rusconi G, Ferrario A, Mariotta L, Gola M, Soldati G. Processing Adipose Tissue Samples in a GMP Environment Standardizes the Use of SVF in Cell Therapy Treatments: Data on 302 Patients. *Biomedicines* 2023; **11**: 2533 [*RCA*] [PMID: 37760974 DOI: 10.3390/biomedicines11092533] [FullText]

26 **Dykstra JA**, Blue ED, Negrão de Assis PL, Weimer JM, Kota DJ. Human adipose-derived stromal vascular fraction: characterization, safety and therapeutic potential in an experimental mouse model of articular injury. *J Stem Cells Regen Med* 2020; **16**: 16-25 [*RCA*] [PMID:

32536767 DOI: 10.46582/jsrm.1601004] [FullText]
27 **Krawczenko A**, Klimczak A. Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration. *Int J Mol Sci* 2022; **23**: 2425 [*RCA*] [PMID: 35269568 DOI: 10.3390/ijms23052425] [FullText] [Full Text(PDF)]
28 **Cai Y**, Li J, Jia C, He Y, Deng C. Therapeutic applications of adipose cell-free derivatives: a review. *Stem Cell Res Ther* 2020; **11**: 312 [*RCA*] [PMID: 32698868 DOI: 10.1186/s13287-020-01831-3] [FullText] [Full Text(PDF)]
29 **Jia Q**, Zhao H, Wang Y, Cen Y, Zhang Z. Mechanisms and applications of adipose-derived stem cell-extracellular vesicles in the inflammation of wound healing. *Front Immunol* 2023; **14**: 1214757 [*RCA*] [PMID: 37520532 DOI: 10.3389/fimmu.2023.1214757] [FullText]
30 **Cai Y**, Zhang F, Feng J, Wu B, Li H, Xiao S, Lu F, Wei Z, Deng C. Long-term follow-up and exploration of the mechanism of stromal vascular fraction gel in chronic wounds. *Stem Cell Res Ther* 2023; **14**: 163 [*RCA*] [PMID: 37337292 DOI: 10.1186/s13287-023-03389-2] [Full Text]
31 **Agaverdiev M**, Shamsov B, Mirzoev S, Vardikyan A, Ramirez ME, Nurmukhametov R, Beilerli A, Zhang B, Gareev I, Pavlov V. MiRNA regulated therapeutic potential of the stromal vascular fraction: Current clinical applications - A systematic review. *Noncoding RNA Res* 2023; **8**: 146-154 [*RCA*] [PMID: 36632616 DOI: 10.1016/j.ncrna.2022.12.003] [FullText] [Full Text(PDF)]
32 **Al-Kharboosh R**, Perera JJ, Bechtle A, Bu G, Quinones-Hinojosa A. Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases. *Clin Transl Med* 2022; **12**: e1093 [*RCA*] [PMID: 36495120 DOI: 10.1002/ctm2.1093] [FullText]
33 **Seo Y**, Shin TH, Kim HS. Current Strategies to Enhance Adipose Stem Cell Function: An Update. *Int J Mol Sci* 2019; **20**: 3827 [*RCA*] [PMID: 31387282 DOI: 10.3390/ijms20153827] [FullText] [Full Text(PDF)]
34 **Bertozzi N**, Simonacci F, Grieco MP, Grignaffini E, Raposio E. The biological and clinical basis for the use of adipose-derived stem cells in the field of wound healing. *Ann Med Surg (Lond)* 2017; **20**: 41-48 [*RCA*] [PMID: 28702186 DOI: 10.1016/j.amsu.2017.06.058] [FullText] [Full Text(PDF)]
35 **François P**, Giraudo L, Veran J, Bertrand B, Dumoulin C, Aboudou H, Grimaud F, Vogtensperger M, Velier M, Arnaud L, Lyonnet L, Simoncini S, Guillet B, Dignat-George F, Magalon J, Sabatier F. Development and Validation of a Fully GMP-Compliant Process for Manufacturing Stromal Vascular Fraction: A Cost-Effective Alternative to Automated Methods. *Cells* 2020; **9**: 2158 [*RCA*] [PMID: 32987708 DOI: 10.3390/cells9102158] [FullText] [Full Text(PDF)]
36 **Rodriguez J**, Pratta AS, Abbassi N, Fabre H, Rodriguez F, Debard C, Adobati J, Boucher F, Mallein-Gerin F, Auxenfans C, Damour O, Mojallal A. Evaluation of Three Devices for the Isolation of the Stromal Vascular Fraction from Adipose Tissue and for ASC Culture: A Comparative Study. *Stem Cells Int* 2017; **2017**: 9289213 [*RCA*] [PMID: 28321259 DOI: 10.1155/2017/9289213] [FullText] [Full Text(PDF)]
37 **Marks PW**. Clear Evidence of Safety and Efficacy Is Needed for Stromal Vascular Fraction Products: Commentary on "Arguments for a Different Regulatory Categorization and Framework for Stromal Vascular Fraction". *Stem Cells Dev* 2020; **29**: 263-265 [*RCA*] [PMID: 31950877 DOI: 10.1089/scd.2020.0011] [FullText]
38 **El-Kadiry AE**, Rafei M, Shammaa R. Cell Therapy: Types, Regulation, and Clinical Benefits. *Front Med (Lausanne)* 2021; **8**: 756029 [*RCA*] [PMID: 34881261 DOI: 10.3389/fmed.2021.756029] [FullText] [Full Text(PDF)]
39 **Perdomo-Pantoja A**, Holmes C, Cottrill E, Rindone AN, Ishida W, Taylor M, Tomberlin C, Lo SL, Grayson WL, Witham TF. Comparison of Freshly Isolated Adipose Tissue-derived Stromal Vascular Fraction and Bone Marrow Cells in a Posterolateral Lumbar Spinal Fusion Model. *Spine (Phila Pa 1976)* 2021; **46**: 631-637 [*RCA*] [PMID: 32991510 DOI: 10.1097/BRS.0000000000003709] [FullText]
40 **Choi JS**, Chae DS, Ryu HA, Kim SW. Transplantation of human adipose tissue derived-SVF enhance liver function through high anti-inflammatory property. *Biochim Biophys Acta Mol Cell Biol Lipids* 2019; **1864**: 158526 [*RCA*] [PMID: 31520775 DOI: 10.1016/j.bbalip.2019.158526] [FullText]
41 **Muthu S**, Jeyaraman M, Kotner MB, Jeyaraman N, Rajendran RL, Sharma S, Khanna M, Rajendran SNS, Oh JM, Gangadaran P, Ahn BC. Evolution of Mesenchymal Stem Cell Therapy as an Advanced Therapeutic Medicinal Product (ATMP)-An Indian Perspective. *Bioengineering (Basel)* 2022; **9**: 111 [*RCA*] [PMID: 35324800 DOI: 10.3390/bioengineering9030111] [FullText] [Full Text(PDF)]
42 **Lee SJ**, Lee CR, Kim KJ, Ryu YH, Kim E, Han YN, Moon SH, Rhie JW. Optimal Condition of Isolation from an Adipose Tissue-Derived Stromal Vascular Fraction for the Development of Automated Systems. *Tissue Eng Regen Med* 2020; **17**: 203-208 [*RCA*] [PMID: 31997256 DOI: 10.1007/s13770-019-00238-3] [FullText]
43 **Sananta P**, I Gede Made Oka R, Suryanto Dradjat PR, Suroto H, Mustamsir E, Kalsum U, Andarini S. Adipose-derived stromal vascular fraction prevent bone bridge formation on growth plate injury in rat (in vivo studies) an experimental research. *Ann Med Surg (Lond)* 2020; **60**: 211-217 [*RCA*] [PMID: 33194176 DOI: 10.1016/j.amsu.2020.09.026] [FullText] [Full Text(PDF)]
44 **Oberbauer E**, Steffenhagen C, Wurzer C, Gabriel C, Redl H, Wolbank S. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. *Cell Regen* 2015; **4**: 7 [*RCA*] [PMID: 26435835 DOI: 10.1186/s13619-015-0020-0] [FullText] [Full Text (PDF)]
45 **Guleria I**, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T. How do I: Evaluate the safety and legitimacy of unproven cellular therapies? *Transfusion* 2022; **62**: 518-532 [*RCA*] [PMID: 35143051 DOI: 10.1111/trf.16814] [FullText]
46 **Kwon H**, Lee S, Kim J, Song SH. Efficacy and safety of stromal vascular fraction on scar revision surgery: a prospective study. *J Dermatolog Treat* 2023; **34**: 2171260 [*RCA*] [PMID: 36661928 DOI: 10.1080/09546634.2023.2171260] [FullText]
47 **Aletto C**, Giordano L, Quaranta M, Zara A, Notarfrancesco D, Maffulli N. Short-term results of intra-articular injections of stromal vascular fraction for early knee osteoarthritis. *J Orthop Surg Res* 2022; **17**: 310 [*RCA*] [PMID: 35690837 DOI: 10.1186/s13018-022-03196-0] [Full Text] [Full Text(PDF)]
48 **Mundluru VK**, Naidu MJ, Mundluru RT, Jeyaraman N, Muthu S, Ramasubramanian S, Jeyaraman M. Non-enzymatic methods for isolation of stromal vascular fraction and adipose-derived stem cells: A systematic review. *World J Methodol* 2024; **14**: 94562 [*RCA*] [PMID: 38983657 DOI: 10.5662/wjm.v14.i2.94562] [FullText] [Full Text(PDF)]
49 **Senesi L**, De Francesco F, Farinelli L, Manzotti S, Gagliardi G, Papalia GF, Riccio M, Gigante A. Mechanical and Enzymatic Procedures to Isolate the Stromal Vascular Fraction From Adipose Tissue: Preliminary Results. *Front Cell Dev Biol* 2019; **7**: 88 [*RCA*] [PMID: 31231649 DOI: 10.3389/fcell.2019.00088] [FullText] [Full Text(PDF)]
50 **You X**, Gao J, Yao Y. Advanced methods to mechanically isolate stromal vascular fraction: A concise review. *Regen Ther* 2024; **27**: 120-125 [*RCA*] [PMID: 38571891 DOI: 10.1016/j.reth.2024.03.020] [FullText] [Full Text(PDF)]
51 **Yaylacı S**, Kaçaroğlu D, Hürkal Ö, Ulaşlı AM. An enzyme-free technique enables the isolation of a large number of adipose-derived stem cells

at the bedside. *Sci Rep* 2023; **13**: 8005 [*RCA*] [PMID: 37198228 DOI: 10.1038/s41598-023-34915-0] [FullText]

52 **Aronowitz JA**, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. *Springerplus* 2015; **4**: 713 [*RCA*] [PMID: 26636001 DOI: 10.1186/s40064-015-1509-2] [FullText] [Full Text(PDF)]

53 **Chen W**, He Z, Li S, Wu Z, Tan J, Yang W, Li G, Pan X, Liu Y, Lyu FJ, Li W. The Effect of Tissue Stromal Vascular Fraction as Compared to Cellular Stromal Vascular Fraction to Treat Anal Sphincter Incontinence. *Bioengineering (Basel)* 2022; **10**: 32 [*RCA*] [PMID: 36671604 DOI: 10.3390/bioengineering10010032] [FullText]

54 **Gentile P**, Calabrese C, De Angelis B, Pizzicannella J, Kothari A, Garcovich S. Impact of the Different Preparation Methods to Obtain Human Adipose-Derived Stromal Vascular Fraction Cells (AD-SVFs) and Human Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Enzymatic Digestion Versus Mechanical Centrifugation. *Int J Mol Sci* 2019; **20**: 5471 [*RCA*] [PMID: 31684107 DOI: 10.3390/ijms20215471] [FullText] [Full Text(PDF)]

55 **Andia I**, Maffulli N, Burgos-Alonso N. Stromal vascular fraction technologies and clinical applications. *Expert Opin Biol Ther* 2019; **19**: 1289-1305 [*RCA*] [PMID: 31544555 DOI: 10.1080/14712598.2019.1671970] [FullText]

56 **van Dongen JA**, Tuin AJ, Spiekman M, Jansma J, van der Lei B, Harmsen MC. Comparison of intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review. *J Tissue Eng Regen Med* 2018; **12**: e261-e274 [*RCA*] [PMID: 28084666 DOI: 10.1002/term.2407] [FullText]

57 **van Dongen JA**, Stevens HP, Parvizi M, van der Lei B, Harmsen MC. The fractionation of adipose tissue procedure to obtain stromal vascular fractions for regenerative purposes. *Wound Repair Regen* 2016; **24**: 994-1003 [*RCA*] [PMID: 27717133 DOI: 10.1111/wrr.12482] [FullText]

58 **Mehling B**, Hric M, Salatkova A, Vetrak R, Santora D, Ovariova M, Mihalyova R, Manvelyan M. A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis. *J Clin Med Res* 2020; **12**: 747-751 [*RCA*] [PMID: 33224377 DOI: 10.14740/jocmr4354] [FullText] [Full Text(PDF)]

59 **Maged A**, Abdelbaset R, Mahmoud AA, Elkasabgy NA. Merits and advances of microfluidics in the pharmaceutical field: design technologies and future prospects. *Drug Deliv* 2022; **29**: 1549-1570 [*RCA*] [PMID: 35612293 DOI: 10.1080/10717544.2022.2069878] [FullText] [Full Text (PDF)]

60 **Ryu H**, Jeon TJ, Kim SM. Editorial Perspective: Advancements in Microfluidics and Biochip Technologies. *Micromachines (Basel)* 2025; **16**: 77 [*RCA*] [PMID: 39858732 DOI: 10.3390/mi16010077] [FullText]

61 **Jović D**, Preradović L, Jović F, Kremenović M, Lukić D, Antonić M, Unčanin N, Jović M. Optimizing adipose-derived stromal vascular fraction storage: Temperature and time impact on cell viability in regenerative medicine. *Medicine (Baltimore)* 2024; **103**: e39859 [*RCA*] [PMID: 39312305 DOI: 10.1097/MD.0000000000039859] [FullText]

62 **Dewi DA**, Chouw A, Sartika CR, Facicilia G, Dirgantara Y, Pratiwi ED, Utami ER, Riswandani J, Wulandari D. Comparison of viability and proliferation potency of stromal vascular fraction stored at different temperature. *Cytotherapy* 2019; **21**: S86 [*RCA*] [DOI: 10.1016/j.jcyt.2019.03.510] [FullText]

63 **Shaik S**, Wu X, Gimble J, Devireddy R. Effects of Decade Long Freezing Storage on Adipose Derived Stem Cells Functionality. *Sci Rep* 2018; **8**: 8162 [*RCA*] [PMID: 29802353 DOI: 10.1038/s41598-018-26546-7] [FullText] [Full Text(PDF)]

64 **Svalgaard JD**, Juul S, Vester-Glovinski PV, Haastrup EK, Ballesteros OR, Lynggaard CD, Jensen AK, Fischer-Nielsen A, Herly M, Munthe-Fog L. Lipoaspirate Storage Time and Temperature: Effects on Stromal Vascular Fraction Quality and Cell Composition. *Cells Tissues Organs* 2020; **209**: 54-63 [*RCA*] [PMID: 32580198 DOI: 10.1159/000507825] [FullText]

65 **Tao Y**, Zhao ZN, Xiang XJ, Liang ZX, Zhao Y. SVF-GEL Cryopreserved for Different Times Exhibits Varied Preservation and Regeneration Potential After Transplantation in a Mouse Model. *Aesthetic Plast Surg* 2023; **47**: 842-851 [*RCA*] [PMID: 36074301 DOI: 10.1007/s00266-022-03065-5] [FullText]

66 **Wu YD**, Li M, Liao X, Li SH, Yan JX, Fan L, She WL, Song JX, Liu HW. Effects of storage culture media, temperature and duration on human adiposederived stem cell viability for clinical use. *Mol Med Rep* 2019; **19**: 2189-2201 [*RCA*] [PMID: 30664198 DOI: 10.3892/mmr.2019.9842] [FullText] [Full Text(PDF)]

67 **Gonda K**, Shigeura T, Sato T, Matsumoto D, Suga H, Inoue K, Aoi N, Kato H, Sato K, Murase S, Koshima I, Yoshimura K. Preserved proliferative capacity and multipotency of human adipose-derived stem cells after long-term cryopreservation. *Plast Reconstr Surg* 2008; **121**: 401-410 [*RCA*] [PMID: 18300956 DOI: 10.1097/01.prs.0000298322.70032.bc] [FullText]

68 **González-Fernández ML**, Pérez-Castrillo S, Ordás-Fernández P, López-González ME, Colaço B, Villar-Suárez V. Study on viability and chondrogenic differentiation of cryopreserved adipose tissue-derived mesenchymal stromal cells for future use in regenerative medicine. *Cryobiology* 2015; **71**: 256-263 [*RCA*] [PMID: 26209137 DOI: 10.1016/j.cryobiol.2015.07.007] [FullText]

69 **Matsumoto D**, Shigeura T, Sato K, Inoue K, Suga H, Kato H, Aoi N, Murase S, Gonda K, Yoshimura K. Influences of preservation at various temperatures on liposuction aspirates. *Plast Reconstr Surg* 2007; **120**: 1510-1517 [*RCA*] [PMID: 18040181 DOI: 10.1097/01.prs.0000288015.70922.e4] [FullText]

70 **Zhang F**, Ren H, Shao X, Zhuang C, Chen Y, Qi N. Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal stem cells for therapeutic application. *PeerJ* 2017; **5**: e3301 [*RCA*] [PMID: 28533959 DOI: 10.7717/peerj.3301] [FullText] [Full Text(PDF)]

71 **Rowe G**, Heng DS, Beare JE, Hodges NA, Tracy EP, Murfee WL, LeBlanc AJ. Stromal Vascular Fraction Reverses the Age-Related Impairment in Revascularization following Injury. *J Vasc Res* 2022; **59**: 343-357 [*RCA*] [PMID: 36075199 DOI: 10.1159/000526002] [Full Text]

72 **Choudhery MS**, Badowski M, Muise A, Pierce J, Harris DT. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. *J Transl Med* 2014; **12**: 8 [*RCA*] [PMID: 24397850 DOI: 10.1186/1479-5876-12-8] [FullText] [Full Text(PDF)]

73 **Ahmed AS**, Sheng MH, Wasnik S, Baylink DJ, Lau KW. Effect of aging on stem cells. *World J Exp Med* 2017; **7**: 1-10 [*RCA*] [PMID: 28261550 DOI: 10.5493/wjem.v7.i1.1] [FullText] [Full Text(PDF)]

74 **Dos-Anjos Vilaboa S**, Navarro-Palou M, Llull R. Age influence on stromal vascular fraction cell yield obtained from human lipoaspirates. *Cytotherapy* 2014; **16**: 1092-1097 [*RCA*] [PMID: 24726656 DOI: 10.1016/j.jcyt.2014.02.007] [FullText]

75 **Szűcs D**, Monostori T, Miklós V, Páhi ZG, Póliska S, Kemény L, Veréb Z. Licensing effects of inflammatory factors and TLR ligands on the regenerative capacity of adipose-derived mesenchymal stem cells. *Front Cell Dev Biol* 2024; **12**: 1367242 [*RCA*] [PMID: 38606318 DOI: 10.3389/fcell.2024.1367242] [FullText]

76 **Mitchell JB**, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, Di Halvorsen Y, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells* 2006;

24: 376-385 [*RCA*] [PMID: 16322640 DOI: 10.1634/stemcells.2005-0234] [FullText]

77 **Debnath T**, Chelluri LK. Standardization and quality assessment for clinical grade mesenchymal stem cells from human adipose tissue. *Hematol Transfus Cell Ther* 2019; **41**: 7-16 [*RCA*] [PMID: 30793099 DOI: 10.1016/j.htct.2018.05.001] [FullText] [Full Text(PDF)]

78 **Haack-Sørensen M**, Follin B, Juhl M, Brorsen SK, Søndergaard RH, Kastrup J, Ekblond A. Culture expansion of adipose derived stromal cells. A closed automated Quantum Cell Expansion System compared with manual flask-based culture. *J Transl Med* 2016; **14**: 319 [*RCA*] [PMID: 27852267 DOI: 10.1186/s12967-016-1080-9] [FullText] [Full Text(PDF)]

79 **Zocchi ML**, Vindigni V, Pagani A, Pirro O, Conti G, Sbarbati A, Bassetto F. Regulatory, ethical, and technical considerations on regenerative technologies and adipose-derived mesenchymal stem cells. *Eur J Plast Surg* 2019; **42**: 531-548 [*RCA*] [DOI: 10.1007/s00238-019-01571-5] [FullText]

80 **François P**, Rusconi G, Arnaud L, Mariotta L, Giraudo L, Minonzio G, Veran J, Bertrand B, Dumoulin C, Grimaud F, Lyonnet L, Casanova D, Giverne C, Cras A, Magalon G, Dignat-George F, Sabatier F, Magalon J, Soldati G. Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions. *Stem Cell Res Ther* 2021; **12**: 373 [*RCA*] [PMID: 34210363 DOI: 10.1186/s13287-021-02445-z] [FullText] [Full Text(PDF)]

81 **Bensemmane L**, Milliat F, Treton X, Linard C. Systemically delivered adipose stromal vascular fraction mitigates radiation-induced gastrointestinal syndrome by immunomodulating the inflammatory response through a CD11b(+) cell-dependent mechanism. *Stem Cell Res Ther* 2023; **14**: 325 [*RCA*] [PMID: 37953266 DOI: 10.1186/s13287-023-03562-7] [FullText]

82 **Silva KR**, Côrtes I, Liechocki S, Carneiro JR, Souza AA, Borojevic R, Maya-Monteiro CM, Baptista LS. Characterization of stromal vascular fraction and adipose stem cells from subcutaneous, preperitoneal and visceral morbidly obese human adipose tissue depots. *PLoS One* 2017; **12**: e0174115 [*RCA*] [PMID: 28323901 DOI: 10.1371/journal.pone.0174115] [FullText] [Full Text(PDF)]

83 **Lopez-Navas L**, Torrents S, Sánchez-Pernaute R, Vives J. Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies. *Stem Cells Transl Med* 2022; **11**: 805-813 [*RCA*] [PMID: 35830540 DOI: 10.1093/stcltm/szac046] [FullText] [Full Text(PDF)]

84 **West CC**, Murray IR, González ZN, Hindle P, Hay DC, Stewart KJ, Péault B. Ethical, legal and practical issues of establishing an adipose stem cell bank for research. *J Plast Reconstr Aesthet Surg* 2014; **67**: 745-751 [*RCA*] [PMID: 24529696 DOI: 10.1016/j.bjps.2014.01.030] [Full Text]

85 **Grizzle WE**. Issues in the Use of Human Tissues to Support Precision Medicine. *J Health Care Poor Underserved* 2019; **30**: 66-78 [*RCA*] [PMID: 31735720 DOI: 10.1353/hpu.2019.0117] [FullText]

86 **Pietrzykowski T**, Smilowska K. The reality of informed consent: empirical studies on patient comprehension-systematic review. *Trials* 2021; **22**: 57 [*RCA*] [PMID: 33446265 DOI: 10.1186/s13063-020-04969-w] [FullText] [Full Text(PDF)]

87 **Williams JS**, Walker RJ, Egede LE. Achieving Equity in an Evolving Healthcare System: Opportunities and Challenges. *Am J Med Sci* 2016; **351**: 33-43 [*RCA*] [PMID: 26802756 DOI: 10.1016/j.amjms.2015.10.012] [FullText]

88 **Stanford FC**. The Importance of Diversity and Inclusion in the Healthcare Workforce. *J Natl Med Assoc* 2020; **112**: 247-249 [*RCA*] [PMID: 32336480 DOI: 10.1016/j.jnma.2020.03.014] [FullText]

89 **Ferreira MY**, Carvalho Junior JDC, Ferreira LM. Evaluating the quality of studies reporting on clinical applications of stromal vascular fraction: A systematic review and proposed reporting guidelines (CLINIC-STRA-SVF). *Regen Ther* 2023; **24**: 332-342 [*RCA*] [PMID: 37662694 DOI: 10.1016/j.reth.2023.08.003] [FullText]

90 **Sharkiya SH**. Quality communication can improve patient-centred health outcomes among older patients: a rapid review. *BMC Health Serv Res* 2023; **23**: 886 [*RCA*] [PMID: 37608376 DOI: 10.1186/s12913-023-09869-8] [FullText]

91 **Simpkin AL**, Armstrong KA. Communicating Uncertainty: a Narrative Review and Framework for Future Research. *J Gen Intern Med* 2019; **34**: 2586-2591 [*RCA*] [PMID: 31197729 DOI: 10.1007/s11606-019-04860-8] [FullText]

92 **Paterick TE**, Patel N, Tajik AJ, Chandrasekaran K. Improving health outcomes through patient education and partnerships with patients. *Proc (Bayl Univ Med Cent)* 2017; **30**: 112-113 [*RCA*] [PMID: 28152110 DOI: 10.1080/08998280.2017.11929552] [FullText]

93 **Jeyaraman N**, Jeyaraman M, Ramasubramanian S, Balaji S, Muthu S. Voices that matter: The impact of patient-reported outcome measures on clinical decision-making. *World J Methodol* 2025; **15**: 98066 [*RCA*] [DOI: 10.5662/wjm.v15.i2.98066] [FullText] [Full Text(PDF)]

94 **Razavi Z**, Soltani M, Souri M, van Wijnen AJ. CRISPR innovations in tissue engineering and gene editing. *Life Sci* 2024; **358**: 123120 [*RCA*] [PMID: 39426588 DOI: 10.1016/j.lfs.2024.123120] [FullText]

95 **Hsu MN**, Chang YH, Truong VA, Lai PL, Nguyen TKN, Hu YC. CRISPR technologies for stem cell engineering and regenerative medicine. *Biotechnol Adv* 2019; **37**: 107447 [*RCA*] [PMID: 31513841 DOI: 10.1016/j.biotechadv.2019.107447] [FullText]

96 **Chen FM**, Liu X. Advancing biomaterials of human origin for tissue engineering. *Prog Polym Sci* 2016; **53**: 86-168 [*RCA*] [PMID: 27022202 DOI: 10.1016/j.progpolymsci.2015.02.004] [FullText]

97 **Rahmati M**, Pennisi CP, Budd E, Mobasheri A, Mozafari M. Biomaterials for Regenerative Medicine: Historical Perspectives and Current Trends. *Adv Exp Med Biol* 2018; **1119**: 1-19 [*RCA*] [PMID: 30406362 DOI: 10.1007/5584_2018_278] [FullText]

98 **Deptuła M**, Zawrzykraj M, Sawicka J, Banach-Kopeć A, Tylingo R, Pikuła M. Application of 3D- printed hydrogels in wound healing and regenerative medicine. *Biomed Pharmacother* 2023; **167**: 115416 [*RCA*] [PMID: 37683592 DOI: 10.1016/j.biopha.2023.115416] [FullText]

99 **Nugud A**, Alghfeli L, Elmasry M, El-Serafi I, El-Serafi AT. Biomaterials as a Vital Frontier for Stem Cell-Based Tissue Regeneration. *Front Cell Dev Biol* 2022; **10**: 713934 [*RCA*] [PMID: 35399531 DOI: 10.3389/fcell.2022.713934] [FullText] [Full Text(PDF)]

100 **Revete A**, Aparicio A, Cisterna BA, Revete J, Luis L, Ibarra E, Segura González EA, Molino J, Reginensi D. Advancements in the Use of Hydrogels for Regenerative Medicine: Properties and Biomedical Applications. *Int J Biomater* 2022; **2022**: 3606765 [*RCA*] [PMID: 36387956 DOI: 10.1155/2022/3606765] [FullText] [Full Text(PDF)]

101 **Zhang Y**, Wang J, Yu C, Xia K, Yang B, Zhang Y, Ying L, Wang C, Huang X, Chen Q, Shen L, Li F, Liang C. Advances in single-cell sequencing and its application to musculoskeletal system research. *Cell Prolif* 2022; **55**: e13161 [*RCA*] [PMID: 34888976 DOI: 10.1111/cpr.13161] [FullText] [Full Text(PDF)]

102 **Choudhary RK**, Choudhary S, Tripathi A. Emergence of the stromal vascular fraction and secretome in regenerative medicine. *World J Stem Cells* 2024; **16**: 896-899 [*RCA*] [PMID: 39493826 DOI: 10.4252/wjsc.v16.i10.896] [FullText] [Full Text(PDF)]

103 **Agostini F**, Rossi FM, Aldinucci D, Battiston M, Lombardi E, Zanolin S, Massarut S, Parodi PC, Da Ponte A, Tessitori G, Pivetta B, Durante C, Mazzucato M. Improved GMP compliant approach to manipulate lipoaspirates, to cryopreserve stromal vascular fraction, and to expand adipose stem cells in xeno-free media. *Stem Cell Res Ther* 2018; **9**: 130 [*RCA*] [PMID: 29751821 DOI: 10.1186/s13287-018-0886-1] [Full Text] [Full Text(PDF)]

104 **Jenio FZ**, Scholes C, Marenah M, Li J, Cowley M, Ebrahimi M, Harrison-Brown M, Murrell WD. Quality in practice: implementation of a clinical outcomes registry in regenerative medicine. *Ann Transl Med* 2019; **7**: 130 [*RCA*] [PMID: 31157251 DOI: 10.21037/atm.2019.02.38] [FullText]

105 **Abou-El-Enein M**, Grainger DW, Kili S. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. *Mol Ther* 2018; **26**: 1172-1176 [*RCA*] [PMID: 29685384 DOI: 10.1016/j.ymthe.2018.04.007] [FullText]

106 **Lapuente JP**, Dos-Anjos S, Blázquez-Martínez A. Intra-articular infiltration of adipose-derived stromal vascular fraction cells slows the clinical progression of moderate-severe knee osteoarthritis: hypothesis on the regulatory role of intra-articular adipose tissue. *J Orthop Surg Res* 2020; **15**: 137 [*RCA*] [PMID: 32272946 DOI: 10.1186/s13018-020-01664-z] [FullText] [Full Text(PDF)]

107 **Goncharov EN**, Koval OA, Nikolaevich Bezuglov E, Engelgard M, Igorevich EI, Velentinovich Kotenko K, Encarnacion Ramirez MJ, Montemurro N. Comparative Analysis of Stromal Vascular Fraction and Alternative Mechanisms in Bone Fracture Stimulation to Bridge the Gap between Nature and Technological Advancement: A Systematic Review. *Biomedicines* 2024; **12**: 342 [*RCA*] [PMID: 38397944 DOI: 10.3390/biomedicines12020342] [FullText]

108 **Piemonti L**, Scholz H, de Jongh D, Kerr-Conte J, van Apeldoorn A, Shaw JAM, Engelse MA, Bunnik E, Mühlemann M, Pal-Kutas K, Scott WE 3rd, Magalon J, Kugelmeier P, Berishvili E. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time. *Transpl Int* 2023; **36**: 11633 [*RCA*] [PMID: 37822447 DOI: 10.3389/ti.2023.11633] [FullText]

Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: https://www.f6publishing.com/helpdesk
https://www.wjgnet.com

© 2025 Baishideng Publishing Group Inc. All rights reserved.